129 related articles for article (PubMed ID: 1334604)
1. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment.
Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F
Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604
[TBL] [Abstract][Full Text] [Related]
2. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
[TBL] [Abstract][Full Text] [Related]
3. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma.
Fu KK; Kai EF; Leung CK
J Clin Pharm Ther; 1995 Jun; 20(3):167-72. PubMed ID: 7593379
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin.
Cavaletti G; Bogliun G; Marzorati L; Zincone A; Marzola M; Colombo N; Tredici G
Cancer; 1995 Mar; 75(5):1141-50. PubMed ID: 7850713
[TBL] [Abstract][Full Text] [Related]
7. Peripheral sensory neuropathy and cisplatin chemotherapy.
Roelofs RI; Hrushesky W; Rogin J; Rosenberg L
Neurology; 1984 Jul; 34(7):934-8. PubMed ID: 6330613
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.
Thompson SW; Davis LE; Kornfeld M; Hilgers RD; Standefer JC
Cancer; 1984 Oct; 54(7):1269-75. PubMed ID: 6088023
[TBL] [Abstract][Full Text] [Related]
10. Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.
Solheim O; Skalleberg J; Warncke T; Ørstavik K; Tropé C; Fosså SD
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):240-249. PubMed ID: 30289161
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced peripheral neurotoxicity: relationship to dose intensity.
Pollera CF; Pietrangeli A; Giannarelli D
Ann Oncol; 1991 Mar; 2(3):212. PubMed ID: 1645988
[No Abstract] [Full Text] [Related]
13. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC).
Bacon M; James K; Zee B
Int J Gynecol Cancer; 2003; 13(4):428-34. PubMed ID: 12911718
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results.
Argyriou AA; Chroni E; Koutras A; Iconomou G; Papapetropoulos S; Polychronopoulos P; Kalofonos HP
Support Care Cancer; 2006 Nov; 14(11):1134-40. PubMed ID: 16622646
[TBL] [Abstract][Full Text] [Related]
15. A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity.
Oriana S; Böhm S; Spatti G; Zunino F; Di Re F
Tumori; 1987 Aug; 73(4):337-40. PubMed ID: 3660470
[TBL] [Abstract][Full Text] [Related]
16. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
[TBL] [Abstract][Full Text] [Related]
17. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.
van den Bent MJ; van Putten WL; Hilkens PH; de Wit R; van der Burg ME
Eur J Cancer; 2002 Feb; 38(3):387-91. PubMed ID: 11818204
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J
J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
[TBL] [Abstract][Full Text] [Related]
19. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function.
Krarup-Hansen A; Fugleholm K; Helweg-Larsen S; Hauge EN; Schmalbruch H; Trojaborg W; Krarup C
Brain; 1993 Oct; 116 ( Pt 5)():1017-41. PubMed ID: 8221046
[TBL] [Abstract][Full Text] [Related]
20. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
